13-May-2008 - The lignan metabolite enterolactone may prevent the spread of prostate cancer by acting at the genetic level, suggests new research that deepens our understanding of the topic.
An in vitro study, led by Mark McCann from AgResearch Grasslands in New Zealand, reports that enterolactone beneficially regulated several key genes, producing important effects on programmed cell death of prostate cancer cells.
McCann, in collaboration with researchers from the University of Ulster, Belfast City Hospital, Cork Institute of Technology, and the University of Reading, reports the data in the journal Molecular Nutrition & Food Research. More...
No comments:
Post a Comment